TrioxBio Inc. is a clinical-stage biotech company specializing in the development of compounds to treat diseases and medical conditions related to the pathological overproduction of Nitric Oxide (NO).

Over 100 white papers and articles have been published documenting how the overproduction of nitric oxide is linked to harmful effects on the human body and strongly believed to be responsible for numerous medical conditions, such as intradialytic hypotension and vasoplegic syndrome (two examples of severe hypotension), migraine and cluster headache.

TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a Nitric Oxide Synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity.

TrioxBio's leading candidate, MTR-107, indicated for the prevention of recurrent intradialytic hypotension, an unmet medical need, received orphan drug designation from the FDA in August 2016.  In addition, its development program received Fast Track designation from this agency in May 2018.  MTR-107 phase IIb clinical study activities planned for Q4 of 2018.

Our mission is our commitment to improving quality of life. By way of our existing products and pending approvals across our various markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas.

News & Media

January 17, 2016:
"TrioxBio Inc. submitted an Orphan-drug designation request to the FDA for the treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH)."
August 29, 2016:
"The FDA's Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouronium diethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period."
March 17, 2018:
"TrioxBio Inc. submitted a Fast Track designation request to the FDA for the treatment and prevention of recurrent intradialytic hypotension (IDH)."
May 02, 2018:
"Dr. Dov Tamarkin was appointed as Chairman of the Board. Dr. Dov Tamarkin, founder and former CEO of Foamix Pharmaceuticals, led that company through the required regulatory process in multiple countries (including the USA) and holds extensive experience in IP, clinical study design, drug manufacturing, and in leading biotech platforms."
May 24, 2018:
"The FDA's Center for Drug Evaluation and Research granted TrioxBio Inc. its Fast Track designation request of S-ethylisothiouronium diethylphosphate (MTR-107) for the reduction in hospitalizations or death in patients with end-stage renal disease undergoing hemodialysis who are predisposed to developing intradialytic hypotension."